ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
89,206.70
-0.81%
S&P 500
5,738.52
-1.78%
Dow Jones
42,579.08
-0.99%
US Dollar vs Yen
147.5185
-0.40%
Brent Oil
70.445
1.59%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Regulus Therapeutics Inc (RGLS)

  7. Regulus Therapeutics Inc (RGLS) ニュース

RGLS

Regulus Therapeutics (RGLS)

Regulus Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:RGLS
日付受信時刻ニュースソース見出しコード企業名
2025/03/0506 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RGLSRegulus Therapeutics Inc
2025/03/0422 : 00PR Newswire (US)Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare ConferenceNASDAQ:RGLSRegulus Therapeutics Inc
2025/02/0422 : 00PR Newswire (US)Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceNASDAQ:RGLSRegulus Therapeutics Inc
2025/02/0107 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
2025/02/0107 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
2025/01/3106 : 14Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RGLSRegulus Therapeutics Inc
2025/01/2921 : 00PR Newswire (US)Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)NASDAQ:RGLSRegulus Therapeutics Inc
2025/01/1607 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
2025/01/1607 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
2025/01/1107 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
2025/01/1107 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
2024/11/2622 : 00PR Newswire (US)Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment ConferencesNASDAQ:RGLSRegulus Therapeutics Inc
2024/11/0904 : 17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:RGLSRegulus Therapeutics Inc
2024/11/0806 : 26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RGLSRegulus Therapeutics Inc
2024/11/0806 : 16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RGLSRegulus Therapeutics Inc
2024/11/0806 : 05PR Newswire (US)Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
2024/10/2505 : 02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RGLSRegulus Therapeutics Inc
2024/10/2503 : 02Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:RGLSRegulus Therapeutics Inc
2024/10/1205 : 02Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:RGLSRegulus Therapeutics Inc
2024/10/0821 : 00PR Newswire (US)Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
2024/08/2821 : 00PR Newswire (US)Regulus Therapeutics Announces Participation at Two Healthcare Investment ConferencesNASDAQ:RGLSRegulus Therapeutics Inc
2024/08/0905 : 24Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RGLSRegulus Therapeutics Inc
2024/08/0905 : 16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RGLSRegulus Therapeutics Inc
2024/08/0905 : 05PR Newswire (US)Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
2024/08/0621 : 00PR Newswire (US)Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:RGLSRegulus Therapeutics Inc
2024/07/3005 : 18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
2024/07/0921 : 00PR Newswire (US)Regulus Therapeutics Announces Participation at Two Healthcare Investment ConferencesNASDAQ:RGLSRegulus Therapeutics Inc
2024/06/2423 : 00AllPennyStocks.comThis Biotech Wasted No Time Stealing The Premarket ShowNASDAQ:RGLSRegulus Therapeutics Inc
2024/06/2420 : 00PR Newswire (US)Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
2024/06/0421 : 00PR Newswire (US)Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® IndexesNASDAQ:RGLSRegulus Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RGLS

最近閲覧した銘柄

FX
USDGBP
US Dollar vs Sterling
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
KO
Coca Cola
COIN
XRPUSD
Ripple
NYSE
JPM
JP Morgan Chase
NYSE
VZ
Verizon Communications
COIN
BTCUSD
Bitcoin
NYSE
DIS
Walt Disney
COIN
SOLUSD
Solana
SPI
SP500
S&P 500
AMEX
XLF
Financial Select Sector
CCOM
SILVER
SILVER
USOTC
RHHBY
Roche (QX)
FX
USDJPY
US Dollar vs Yen
AMEX
XLV
Health Care Select Sector
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有

広告を削除する

サインアップして広告なしのエクスペリエンスを体験してください

広告なし

今すぐ試してください

広告を残す